Publication Year

Chang Y, Huynh CTT, Bastin KM, Rivera BN, Siddens LK, Tilton SC. 2020. Classifying polycyclic aromatic hydrocarbons by carcinogenic potency using in vitro biosignatures. Toxicol in Vitro 69:104991, doi: 10.1016/j.tiv.2020.104991.

Neier K, Montrose L, Chen K, Malloy M, Jones T, Svoboda L, et al. 2020. Short- and long-term effects of perinatal phthalate exposures on metabolic pathways in the mouse liver. Environ Epigenet 6(1):dvaa017; doi: 10.1093/eep/dvaa017.

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198. doi: 10.14740/gr1167.

Rivera BN, Ghetu C, Adams K, Anderson K, Tilton S. A novel approach to forming sufficiently similar mixtures from environmental exposure data. Pacific Northwest Association of Toxicologists Annual Meeting (virtual), November 2020.

Rivera BN, Ghetu C, Rohlman D, Adams K, Anderson K. A comprehensive comparison of indoor vs outdoor air quality across the United States. Society of Environmental Toxicology and Chemistry, virtual meeting, November 2020.

Cohen S, Reichert H, Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. ISPOR (International Society for Pharmacoeconomics and Outcomes Research, Inc.) virtual conference, May 2020.

Cekola P, Henrickson A, Cohen SS, Reichert H, Ararujo Torres K, Hulsey A. Growth and tolerance with an amino acid formula at a children’s center: A two-year retrospective review. Poster presented to North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), November 2020.

Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. 2020. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 50(8)685-706; doi: 10.1080/10408444.2020.1823934.

Fryzek J, Suh M, Movva N, Bylsma L. 2020. Protocol: Systematic literature review and meta-analysis of respiratory syncytial virus (RSV) testing patterns, RSV burden, and RSV clinical sequalae among infants and children up to 5 years of age living in the United States. PROSPERO CRD42020162991.

Parker J, Boles C, Leleck O, Buerger AN, Egnot N, Sunderman A, et al. 2020. Advancing toward normal operations for arenas and stadiums. Toxicol Ind Health 36(9):718–727.

Wikoff D, Lewis JR, Erraguntla N, Franzen A, Foreman J. 2020. Facilitation of risk assessment with evidence-based methods — A framework for use of systematic mapping and systematic reviews in determining hazard, developing toxicity values, and characterizing uncertainty. Regul Toxicol Pharmacol 118:104790; doi: 10.1016/j.yrtph.2020.104790. PMID: 33038430.

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp 8(6):e00676; doi: 10.1002/prp2.676.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.